13.06 -0.03 (-0.23%) | 02-11 16:19 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 15.33 | 1-year : | 17.91 |
Resists | First : | 13.13 | Second : | 15.33 |
Pivot price | 12.59 ![]() |
|||
Supports | First : | 10.84 | Second : | 9.43 |
MAs | MA(5) : | 13.03 ![]() |
MA(20) : | 12.11 ![]() |
MA(100) : | 8.93 ![]() |
MA(250) : | 8.87 ![]() |
|
MACD | MACD : | 0.7 ![]() |
Signal : | 0.6 ![]() |
%K %D | K(14,3) : | 96.8 ![]() |
D(3) : | 96.4 ![]() |
RSI | RSI(14): 77.7 ![]() |
|||
52-week | High : | 14.77 | Low : | 4.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ FNA ] has closed below upper band by 31.0%. Bollinger Bands are 7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 13.09 - 13.16 | 13.16 - 13.22 |
Low: | 12.88 - 12.96 | 12.96 - 13.03 |
Close: | 12.93 - 13.06 | 13.06 - 13.18 |
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Mon, 10 Feb 2025
Grabar Law Office is Investigating Claims on Behalf of - GlobeNewswire
Thu, 30 Jan 2025
Strength Seen in Paragon 28, Inc. (FNA): Can Its 8.3% Jump Turn into More Strength? - Yahoo Finance
Wed, 29 Jan 2025
Zimmer Biomet to buy Paragon 28 for $1.2B - Mass Device
Wed, 29 Jan 2025
Zimmer Biomet Snaps Up Paragon 28 In $1.2 Billion Deal: Details - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 84 (M) |
Shares Float | 40 (M) |
Held by Insiders | 40.5 (%) |
Held by Institutions | 60.7 (%) |
Shares Short | 3,730 (K) |
Shares Short P.Month | 3,550 (K) |
EPS | -0.68 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.66 |
Profit Margin | -23 % |
Operating Margin | -13.6 % |
Return on Assets (ttm) | -8.4 % |
Return on Equity (ttm) | -33.8 % |
Qtrly Rev. Growth | 18.1 % |
Gross Profit (p.s.) | 2.26 |
Sales Per Share | 2.92 |
EBITDA (p.s.) | -0.26 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -40 (M) |
Levered Free Cash Flow | -29 (M) |
PE Ratio | -19.5 |
PEG Ratio | 0 |
Price to Book value | 7.82 |
Price to Sales | 4.47 |
Price to Cash Flow | -27.22 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |